cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/k4l-frq-6p7
title: Brachiopoda Duméril, 1805

description: Digital Specimen for the physical specimen hosted at Tallinn University of Technology.
DOI: 10.3886/e243557
title: HHS DRIVE

description: This data is what is visualized in the HHS DRIVE dashboard.
description: (Downloaded 1/10/2026)
DOI: 10.3886/e243557v1
title: HHS DRIVE

description: This data is what is visualized in the HHS DRIVE dashboard.
description: (Downloaded 1/10/2026)
DOI: 10.15468/dl.mxhsny
title: Occurrence Download

description: A dataset containing 30030 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Streptopelia roseogrisea"
 ]
}

 The dataset includes 30030 records from 196 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003341-260108223611665/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.3886/e243558
title: Weekly Cumulative Estimated Number of Updated 2023-24 COVID-19 Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims

description: Weekly Cumulative Estimated Number of Updated 2023-24 COVID-19 Vaccinations Administered in Pharmacies and Physical Medical Offices, Adults 18 Years and Older, United States

• Estimated number of updated COVID-19 vaccinations among adults 18 years and older is assessed through IQVIA (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices.

• Starting in September 2023, the CDC recommended the updated 2023-2024 COVID-19 vaccine for adults ages 18 years and older.
Read less
description: (Downloaded 1/10/2026)
DOI: 10.3886/e243558v1
title: Weekly Cumulative Estimated Number of Updated 2023-24 COVID-19 Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims

description: Weekly Cumulative Estimated Number of Updated 2023-24 COVID-19 Vaccinations Administered in Pharmacies and Physical Medical Offices, Adults 18 Years and Older, United States

• Estimated number of updated COVID-19 vaccinations among adults 18 years and older is assessed through IQVIA (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices.

• Starting in September 2023, the CDC recommended the updated 2023-2024 COVID-19 vaccine for adults ages 18 years and older.
Read less
description: (Downloaded 1/10/2026)
DOI: 10.3886/e243559
title: Weekly Differences in Cumulative Percentage of Children Ages 6 Months -17 Years who are up to date with the updated 2023-24 COVID-19 Vaccine, by Selected Demographics

description: • Weekly COVID-19 vaccination coverage estimates among children 6 months to 17 years is assessed through the National Immunization Survey (https://www.cdc.gov/vaccines/imz-managers/nis/about.html).

• Weekly estimates of COVID-19 vaccination coverage among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM) (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-ccm). Beginning January 2, 2024, the NIS-CCM was discontinued, and questions regarding receipt of COVID-19 vaccination among children were added to the NIS-Flu (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-cim).

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19.
Read less
description: (Downloaded 1/10/2026)
DOI: 10.3886/e243559v1
title: Weekly Differences in Cumulative Percentage of Children Ages 6 Months -17 Years who are up to date with the updated 2023-24 COVID-19 Vaccine, by Selected Demographics

description: • Weekly COVID-19 vaccination coverage estimates among children 6 months to 17 years is assessed through the National Immunization Survey (https://www.cdc.gov/vaccines/imz-managers/nis/about.html).

• Weekly estimates of COVID-19 vaccination coverage among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM) (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-ccm). Beginning January 2, 2024, the NIS-CCM was discontinued, and questions regarding receipt of COVID-19 vaccination among children were added to the NIS-Flu (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-cim).

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19.
Read less
description: (Downloaded 1/10/2026)
DOI: 10.6084/m9.figshare.31046223
title: Plate lattice structure design based on stress field aligned parameterization

description: The plate lattice have promising applications in designing high strength-to-weight ratio structures with volume constraints. Compared to cellular structures infilled with isotropic unit cells, stress field aligned plate lattice structures exhibit higher stiffness in single load cases. This article proposes an optimization design method for generating optimal 3D plate lattice structures based on stress field aligned parameterization. First, the singularity separated parameterization is used to partition the model into the singular regions and singularity-free region, where a parameterization is constructed. Second, in the singularity-free region, a primary lattice structure is generated by extracting isosurfaces from the parameterization. Third, for the singular regions, a strain-adaptive lattice infilling method is proposed to generate plate lattice structures that enhance global stiffness. Experimental results demonstrate the effectiveness of our method in designing high strength-to-weight plate lattice structures.
DOI: 10.6084/m9.figshare.31046223.v1
title: Plate lattice structure design based on stress field aligned parameterization

description: The plate lattice have promising applications in designing high strength-to-weight ratio structures with volume constraints. Compared to cellular structures infilled with isotropic unit cells, stress field aligned plate lattice structures exhibit higher stiffness in single load cases. This article proposes an optimization design method for generating optimal 3D plate lattice structures based on stress field aligned parameterization. First, the singularity separated parameterization is used to partition the model into the singular regions and singularity-free region, where a parameterization is constructed. Second, in the singularity-free region, a primary lattice structure is generated by extracting isosurfaces from the parameterization. Third, for the singular regions, a strain-adaptive lattice infilling method is proposed to generate plate lattice structures that enhance global stiffness. Experimental results demonstrate the effectiveness of our method in designing high strength-to-weight plate lattice structures.
DOI: 10.6084/m9.figshare.30553027
title: Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

description: Despite declining lung cancer death rates, minoritized patients still face health disparities compared to White patients. This study examines treatment preferences and decision-making differences among patients with non-small cell lung cancer (NSCLC) and physicians from different racial and ethnic backgrounds in the US. Two cross-sectional online surveys were conducted from March to May 2023. Respondents were recruited from an NSCLC community and research panel. Recruitment goals were set to ensure diversity, by having African American or Black (hereafter, Black), Asian, Hispanic, and White patients and physicians included. Data were summarized using descriptive statistics. Across all racial and ethnic groups (<i>N</i> = 157), patients reported that extending life was the most important treatment attribute. Hispanic patients assigned more importance to treatment side effect (SE) risks compared to Asian, Black, and White patients. Larger proportions of Asian (63%) and White (73%) patients prioritized quality over quantity of life compared to Black (43%) and Hispanic (40%) patients. All physician groups ranked expected overall survival, progression-free survival, and duration of response as the top three treatment attributes. On a scale of 1 (high) to 10 (low), Black physicians expressed less concern about potential SEs (6.6) than other physician groups (≤5.3). Cost of treatment was consistently ranked with lower importance; however, over 80% of Black and Hispanic physicians thought that patient out-of-pocket costs or financial status were somewhat more or very important to their treatment recommendations. Patients and physicians of different racial and ethnic backgrounds may place varying importance on several treatment attributes.
DOI: 10.6084/m9.figshare.30553027.v2
title: Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

description: Despite declining lung cancer death rates, minoritized patients still face health disparities compared to White patients. This study examines treatment preferences and decision-making differences among patients with non-small cell lung cancer (NSCLC) and physicians from different racial and ethnic backgrounds in the US. Two cross-sectional online surveys were conducted from March to May 2023. Respondents were recruited from an NSCLC community and research panel. Recruitment goals were set to ensure diversity, by having African American or Black (hereafter, Black), Asian, Hispanic, and White patients and physicians included. Data were summarized using descriptive statistics. Across all racial and ethnic groups (<i>N</i> = 157), patients reported that extending life was the most important treatment attribute. Hispanic patients assigned more importance to treatment side effect (SE) risks compared to Asian, Black, and White patients. Larger proportions of Asian (63%) and White (73%) patients prioritized quality over quantity of life compared to Black (43%) and Hispanic (40%) patients. All physician groups ranked expected overall survival, progression-free survival, and duration of response as the top three treatment attributes. On a scale of 1 (high) to 10 (low), Black physicians expressed less concern about potential SEs (6.6) than other physician groups (≤5.3). Cost of treatment was consistently ranked with lower importance; however, over 80% of Black and Hispanic physicians thought that patient out-of-pocket costs or financial status were somewhat more or very important to their treatment recommendations. Patients and physicians of different racial and ethnic backgrounds may place varying importance on several treatment attributes.
DOI: 10.6084/m9.figshare.30553027.v1
title: Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

description: Despite declining lung cancer death rates, minoritized patients still face health disparities compared to White patients. This study examines treatment preferences and decision-making differences among patients with non-small cell lung cancer (NSCLC) and physicians from different racial and ethnic backgrounds in the US. Two cross-sectional online surveys were conducted from March-May 2023. Respondents were recruited from an NSCLC community and research panel. Recruitment goals were set to ensure diversity, by having African American or Black (hereafter, Black), Asian, Hispanic, and White patients and physicians included. Data were summarized using descriptive statistics. Across all racial and ethnic groups (N = 157), patients reported that extending life was the most important treatment attribute. Hispanic patients assigned more importance to treatment side effect (SE) risks compared to Asian, Black, and White patients. Larger proportions of Asian (63%) and White (73%) patients prioritized quality over quantity of life compared to Black (43%) and Hispanic (40%) patients. All physician groups ranked expected overall survival, progression-free survival, and duration of response as the top three treatment attributes. On a scale of 1 (high) to 10 (low), Black physicians expressed less concern about potential SEs (6.6) than other physician groups (≤5.3). Cost of treatment was consistently ranked with lower importance; however, over 80% of Black and Hispanic physicians thought that patient out-of-pocket costs or financial status were somewhat more or very important to their treatment recommendations. Patients and physicians of different racial and ethnic backgrounds may place varying importance on several treatment attributes.
DOI: 10.6084/m9.figshare.30719789
title: Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

description: Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retrospective study of claims from the Japanese Medical Data Vision (MDV) database reported that first-line (1 L) DRd may improve outcomes versus second-line or later treatment in patients with TIE NDMM. Data from this study underwent further analysis to investigate the correlation between 1 L DRd duration of treatment (DoT) and overall survival (OS). DoT and OS outcomes were also assessed in subgroups defined by age (&lt;75, ≥75 to &lt;80, ≥80 years) and Charlson Comorbidity Index (CCI; low [score 0], medium [1 or 2], high [3 or 4] or very high [≥5]). Of 35,581 patients in the MDV database with a diagnosis of MM between January 1, 2016 and October 31, 2023, 200 patients (median age 77 years, median time from MM diagnosis 16 days) were prescribed 1 L DRd and had baseline/demographic data available at the start of treatment. After a median follow-up of 12.8 months, 1 L DRd DoT (median 26.9 months) showed high-positive correlation with OS (not reached) using Pearson’s (<i>r</i> = 0.832), Spearman’s rank (<i>r<sub>s</sub></i>=0.777), Kendall’s Tau (<i>τ<sub>b</sub></i>=0.703), and Fleischer’s (Corr [DoT, OS] = 0.789) coefficients in the overall population, and moderate- or high-positive correlation with OS across age and CCI score subgroups. These findings suggest that 1 L DRd DoT is a potential predictor of OS when used in Japanese clinical practice.
DOI: 10.6084/m9.figshare.30719789.v1
title: Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

description: Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retrospective study of claims from the Japanese Medical Data Vision (MDV) database reported that first-line (1 L) DRd may improve outcomes versus second-line or later treatment in patients with TIE NDMM. Data from this study underwent further analysis to investigate the correlation between 1 L DRd duration of treatment (DoT) and overall survival (OS). DoT and OS outcomes were also assessed in subgroups defined by age (&lt;75, ≥75 to &lt;80, ≥80 years) and Charlson Comorbidity Index (CCI; low [score 0], medium [1 or 2], high [3 or 4] or very high [≥5]). Of 35,581 patients in the MDV database with a diagnosis of MM between January 1, 2016 and October 31, 2023, 200 patients (median age 77 years, median time from MM diagnosis 16 days) were prescribed 1 L DRd and had baseline/demographic data available at the start of treatment. After a median follow-up of 12.8 months, 1 L DRd DoT (median 26.9 months) showed high-positive correlation with OS (not reached) using Pearson’s (<i>r</i> = 0.832), Spearman’s rank (<i>r<sub>s</sub></i>=0.777), Kendall’s Tau (<i>τ<sub>b</sub></i>=0.703), and Fleischer’s (Corr [DoT, OS] = 0.789) coefficients in the overall population, and moderate- or high-positive correlation with OS across age and CCI score subgroups. These findings suggest that 1 L DRd DoT is a potential predictor of OS when used in Japanese clinical practice.
DOI: 10.6084/m9.figshare.30551126
title: How voice biomarkers have been used in heart failure management: a scoping review

description: Voice biomarkers have been increasingly applied in disease diagnosis and monitoring because of their non-invasive, low-cost, and easily accessible features. This scoping review aimed to summarize existing evidence on voice biomarkers used in heart failure management and to describe their collection, processing, and analysis methods. Four databases (PubMed, CINAHL, Scopus, and IEEE Xplore) were searched from inception to January 10, 2024. Two reviewers independently screened studies and extracted data using a predesigned form. The review followed the Joanna Briggs Institute framework and the PRISMA-ScR guideline. Nineteen studies published between 2010 and 2023 were included. Voice biomarkers were applied for diagnosis or differential diagnosis (9/19) and for assessing or monitoring disease progression (10/19). Voice/speech (11/19) were the most common biomarkers, typically collected via microphones (6/19), phones (3/19), or applications (3/19). Common processing methods included segmentation (9/19), feature extraction (9/19), denoising (8/19), and resampling (7/19). Most studies (12/19) developed new algorithms for data analysis. Model performance was mainly evaluated by accuracy (10/19), sensitivity (7/19), and specificity (6/19). This review highlights the potential of voice/speech biomarkers in heart failure management. Their non-invasive and accessible nature supports their integration into clinical monitoring. However, standardized procedures for data collection, processing, and analysis should be established through multidisciplinary collaboration to enable reliable clinical application.
DOI: 10.6084/m9.figshare.30551126.v1
title: How voice biomarkers have been used in heart failure management: a scoping review

description: Voice biomarkers have been increasingly applied in disease diagnosis and monitoring because of their non-invasive, low-cost, and easily accessible features. This scoping review aimed to summarize existing evidence on voice biomarkers used in heart failure management and to describe their collection, processing, and analysis methods. Four databases (PubMed, CINAHL, Scopus, and IEEE Xplore) were searched from inception to January 10, 2024. Two reviewers independently screened studies and extracted data using a predesigned form. The review followed the Joanna Briggs Institute framework and the PRISMA-ScR guideline. Nineteen studies published between 2010 and 2023 were included. Voice biomarkers were applied for diagnosis or differential diagnosis (9/19) and for assessing or monitoring disease progression (10/19). Voice/speech (11/19) were the most common biomarkers, typically collected via microphones (6/19), phones (3/19), or applications (3/19). Common processing methods included segmentation (9/19), feature extraction (9/19), denoising (8/19), and resampling (7/19). Most studies (12/19) developed new algorithms for data analysis. Model performance was mainly evaluated by accuracy (10/19), sensitivity (7/19), and specificity (6/19). This review highlights the potential of voice/speech biomarkers in heart failure management. Their non-invasive and accessible nature supports their integration into clinical monitoring. However, standardized procedures for data collection, processing, and analysis should be established through multidisciplinary collaboration to enable reliable clinical application.
DOI: 10.3886/e243560
title: Weekly Cumulative Percentage of Children Ages 6 Months -17 Years who are up to date with the updated 2023-24 COVID-19 Vaccine, by Jurisdiction

description: • Weekly COVID-19 vaccination coverage estimates among children 6 months to 17 years is assessed through the National Immunization Survey (https://www.cdc.gov/vaccines/imz-managers/nis/about.html).

• Weekly estimates of COVID-19 vaccination coverage among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM) (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-ccm). Beginning January 2, 2024, the NIS-CCM was discontinued, and questions regarding receipt of COVID-19 vaccination among children were added to the NIS-Flu (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-cim).

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19.
Read less
description: (Downloaded 1/10/2026)
DOI: 10.3886/e243560v1
title: Weekly Cumulative Percentage of Children Ages 6 Months -17 Years who are up to date with the updated 2023-24 COVID-19 Vaccine, by Jurisdiction

description: • Weekly COVID-19 vaccination coverage estimates among children 6 months to 17 years is assessed through the National Immunization Survey (https://www.cdc.gov/vaccines/imz-managers/nis/about.html).

• Weekly estimates of COVID-19 vaccination coverage among children through December 31, 2023, were calculated using data from the National Immunization Survey-Child COVID Module (NIS-CCM) (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-ccm). Beginning January 2, 2024, the NIS-CCM was discontinued, and questions regarding receipt of COVID-19 vaccination among children were added to the NIS-Flu (https://www.cdc.gov/vaccines/imz-managers/nis/about.html#nis-cim).

• Starting in September 2023, the CDC recommended the 2023-2024 updated COVID-19 vaccine to protect against serious illness from COVID-19.
Read less
description: (Downloaded 1/10/2026)
DOI: 10.15468/dl.r76a25
title: Occurrence Download

description: A dataset containing 47 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Protaetia orientalis sakaii Kobayashi, 1994)",
 "HasCoordinate is true"
 ]
}

 The dataset includes 47 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0089103-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.dgkguw
title: Occurrence Download

description: A dataset containing 237 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Trypoxylus dichotomus septentrionalis Kôno, 1931)",
 "HasCoordinate is true"
 ]
}

 The dataset includes 237 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0089104-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.myacnc
title: Occurrence Download

description: A dataset containing 2 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Procambarus cubensis rivalis (Faxon, 1912))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 2 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0089105-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.